Medtronic Warning Letters Lifted, Clearing Path For CRM, Neurostim PMAs
This article was originally published in The Gray Sheet
Executive Summary
A barrier to FDA approval for several of Medtronic's core product candidates was lifted with the firm's announcement March 9 that longstanding warning letters had been resolved.